Neurotrophin	O
p75	O
receptor	O
(	O
p75NTR	O
)	O
promotes	O
endothelial	B-Cell
cell	I-Cell
apoptosis	O
and	O
inhibits	O
angiogenesis	O
:	O
implications	O
for	O
diabetes	O
-	O
induced	O
impaired	O
neovascularization	O
in	O
ischemic	O
limb	B-Organ
muscles	I-Organ
.	O

Diabetes	O
impairs	O
endothelial	B-Cell
function	O
and	O
reparative	O
neovascularization	O
.	O

The	O
p75	O
receptor	O
of	O
neurotrophins	O
(	O
p75	O
(	O
NTR	O
)	O
)	O
,	O
which	O
is	O
scarcely	O
present	O
in	O
healthy	O
endothelial	B-Cell
cells	I-Cell
(	O
ECs	B-Cell
)	O
,	O
becomes	O
strongly	O
expressed	O
by	O
capillary	B-Cell
ECs	I-Cell
after	O
induction	O
of	O
peripheral	B-Tissue
ischemia	O
in	O
type	O
-	O
1	O
diabetic	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
gene	O
transfer	O
-	O
induced	O
p75	O
(	O
NTR	O
)	O
expression	O
impairs	O
the	O
survival	O
,	O
proliferation	O
,	O
migration	O
,	O
and	O
adhesion	O
capacities	O
of	O
cultured	O
ECs	B-Cell
and	O
endothelial	B-Cell
progenitor	I-Cell
cells	I-Cell
(	O
EPCs	B-Cell
)	O
and	O
inhibits	O
angiogenesis	O
in	O
vitro	O
.	O

Moreover	O
,	O
intramuscular	B-Immaterial_anatomical_entity
p75	O
(	O
NTR	O
)	O
gene	O
delivery	O
impairs	O
neovascularization	O
and	O
blood	B-Organism_substance
flow	O
recovery	O
in	O
a	O
mouse	O
model	O
of	O
limb	B-Organism_subdivision
ischemia	O
.	O

These	O
disturbed	O
functions	O
are	O
associated	O
with	O
suppression	O
of	O
signaling	O
mechanisms	O
implicated	O
in	O
EC	B-Cell
survival	O
and	O
angiogenesis	O
.	O

In	O
fact	O
,	O
p75	O
(	O
NTR	O
)	O
depresses	O
the	O
VEGF	O
-	O
A	O
/	O
Akt	O
/	O
eNOS	O
/	O
NO	O
pathway	O
and	O
additionally	O
reduces	O
the	O
mRNA	O
levels	O
of	O
ITGB1	O
[	O
beta	O
(	O
1	O
)	O
integrin	O
]	O
,	O
BIRC5	O
(	O
survivin	O
)	O
,	O
PTTG1	O
(	O
securin	O
)	O
and	O
VEZF1	O
.	O

Diabetic	O
mice	O
,	O
which	O
typically	O
show	O
impaired	O
postischemic	O
muscular	B-Organ
neovascularization	O
and	O
blood	B-Organism_substance
perfusion	O
recovery	O
,	O
have	O
these	O
defects	O
corrected	O
by	O
intramuscular	B-Immaterial_anatomical_entity
gene	O
transfer	O
of	O
a	O
dominant	O
negative	O
mutant	O
form	O
of	O
p75	O
(	O
NTR	O
)	O
.	O

Collectively	O
,	O
our	O
data	O
newly	O
demonstrate	O
the	O
antiangiogenic	O
action	O
of	O
p75	O
(	O
NTR	O
)	O
and	O
open	O
new	O
avenues	O
for	O
the	O
therapeutic	O
use	O
of	O
p75	O
(	O
NTR	O
)	O
inhibition	O
to	O
combat	O
diabetes	O
-	O
induced	O
microvascular	B-Tissue
liabilities	O
.	O

